Lucentis Price Concessions Win Partial Victory; NICE Clears Drug With Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain's cost watchdog NICE changed its mind on Lucentis, and now recommends it for treating diabetic macular edema, after Novartis offered a steeper discount – but the eye drug’s price tag remains high, so only a subgroup of British patients will receive it.